Alzheimer's disease: Unique markers for diagnosis & new treatment modalities

Alzheimer's disease: Unique markers for diagnosis & new treatment modalities

Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease. In humans, AD becomes symptomatic only after brain changes occur over years or decades. Three contiguous phases of AD have been proposed: (i) the AD pathophysiologic process, (ii) mild cognitive impairment due...

Full description

Bibliographic Details
Main Authors: Aggarwal, Neelum T., Shah, Raj C., Bennett, David A.
Format: Online
Language:English
Published: Medknow Publications & Media Pvt Ltd 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683821/
id pubmed-4683821
recordtype oai_dc
spelling pubmed-46838212015-12-28 Alzheimer's disease: Unique markers for diagnosis & new treatment modalities Aggarwal, Neelum T. Shah, Raj C. Bennett, David A. Review Article Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease. In humans, AD becomes symptomatic only after brain changes occur over years or decades. Three contiguous phases of AD have been proposed: (i) the AD pathophysiologic process, (ii) mild cognitive impairment due to AD, and (iii) AD dementia. Intensive research continues around the world on unique diagnostic markers and interventions associated with each phase of AD. In this review, we summarize the available evidence and new therapeutic approaches that target both amyloid and tau pathology in AD and discuss the biomarkers and pharmaceutical interventions available and in development for each AD phase. Medknow Publications & Media Pvt Ltd 2015-10 /pmc/articles/PMC4683821/ /pubmed/26609028 http://dx.doi.org/10.4103/0971-5916.169193 Text en Copyright: © Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution NonCommercial ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Aggarwal, Neelum T.
Shah, Raj C.
Bennett, David A.
spellingShingle Aggarwal, Neelum T.
Shah, Raj C.
Bennett, David A.
Alzheimer's disease: Unique markers for diagnosis & new treatment modalities
author_facet Aggarwal, Neelum T.
Shah, Raj C.
Bennett, David A.
author_sort Aggarwal, Neelum T.
title Alzheimer's disease: Unique markers for diagnosis & new treatment modalities
title_short Alzheimer's disease: Unique markers for diagnosis & new treatment modalities
title_full Alzheimer's disease: Unique markers for diagnosis & new treatment modalities
title_fullStr Alzheimer's disease: Unique markers for diagnosis & new treatment modalities
title_full_unstemmed Alzheimer's disease: Unique markers for diagnosis & new treatment modalities
title_sort alzheimer's disease: unique markers for diagnosis & new treatment modalities
description Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease. In humans, AD becomes symptomatic only after brain changes occur over years or decades. Three contiguous phases of AD have been proposed: (i) the AD pathophysiologic process, (ii) mild cognitive impairment due to AD, and (iii) AD dementia. Intensive research continues around the world on unique diagnostic markers and interventions associated with each phase of AD. In this review, we summarize the available evidence and new therapeutic approaches that target both amyloid and tau pathology in AD and discuss the biomarkers and pharmaceutical interventions available and in development for each AD phase.
publisher Medknow Publications & Media Pvt Ltd
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683821/
_version_ 1613514323287605248

Similar Items